CompanyOverview|NYSE:LLY] The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), is back in the green ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

In the sleepy suburb of Bagsværd, a 25-minute train ride from Denmark’s capital of Copenhagen, weight-loss drugmaker Novo Nordisk is everywhere. Street after street is filled with the company ...

Eli Lilly and Company traded as low as $718.81 and last traded at $718.89. Approximately 663,002 shares changed hands during trading, a decline of 80% from the average daily volume of 3,354,701 ...

India supplies nearly 50% of U.S. generic drugs; tariffs could disrupt $13 billion in exports. A Section 232 probe may delay pharma tariffs until late 2025 or beyond. Markets are messy—but the ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares closed yesterday at $726.24.

Novo Nordisk’s India launch comes amid growing demand for glucagon-like peptide-1 (GLP-1)-based therapies, and follows the recent rollout of Mounjaro by Eli Lilly, a dual GLP-1/glucose-dependent ...

One of them is the pharmaceutical industry. However, some major executives in the sector are not optimistic, including Eli Lilly's (NYSE: LLY) CEO, David Ricks. Start Your Mornings Smarter!

April 8 - Eli Lilly (NYSE:LLY) shares rose about 5% Tuesday morning after Goldman Sachs (NYSE:GS) upgraded the pharmaceutical giant to Buy from Neutral, citing confidence in its leadership in the fast ...

INDIANAPOLIS — Eli Lilly and Company says it's suing an Indianapolis-based weight loss clinic that it claims is misleading patients about drugs being sold. Lilly claims Premier Weight Loss is selling ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.